Brief: Abbvie To Acquire Immunogen, Including Cancer Therapy Elahere®, Expanding Solid Tumor Portfolio

ImmunoGen

30/11/2023 13:04

Nov 30 (Reuters) - Abbvie Inc  ABBV.N :
    * ABBVIE TO ACQUIRE IMMUNOGEN, INCLUDING ITS FLAGSHIP CANCER
THERAPY ELAHERE® (MIRVETUXIMAB SORAVTANSINE-GYNX), EXPANDING
SOLID TUMOR PORTFOLIO
    * ABBVIE TO ACQUIRE IMMUNOGEN, INCLUDING ITS FLAGSHIP CANCER
THERAPY ELAHERE® (MIRVETUXIMAB SORAVTANSINE-GYNX), EXPANDING
SOLID TUMOR PORTFOLIO
    * ABBVIE INC - PROPOSED DEAL FOR TRANSACTION VALUED AT
$31.26 PER
SHARE IN CASH
    * ABBVIE INC: TRANSACTION VALUED AT $31.26 PER SHARE IN
CASH, FOR
A TOTAL EQUITY VALUE OF APPROXIMATELY $10.1 BILLION
    * ABBVIE INC - PROPOSED TRANSACTION IS EXPECTED TO BE
ACCRETIVE TO
DILUTED EARNINGS PER SHARE (EPS) BEGINNING IN 2027
    * ABBVIE INC - TRANSACTION IS EXPECTED TO CLOSE IN MIDDLE OF
2024

Source text for Eikon:  ID:nPn3QS9sJa 
Further company coverage:  ABBV.N 

 ((Reuters.Briefs@thomsonreuters.com;))